MYNZ — Mainz Biomed NV Share Price
0.000.00%
Last trade - 00:00- $7.47m
- $3.47m
- $0.89m
- 41
- 18
- 22
- 16
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.24 | ||
| Price to Tang. Book | 2.47 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.35 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -256.1% | ||
| Return on Equity | -465.82% | ||
| Operating Margin | -2088.06% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 0.49 | 0.58 | 0.53 | 0.9 | 0.89 | 1.25 | 1.16 | 26.01% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Mainz Biomed N.V. is a Germany based molecular genetics cancer diagnostic company. The Company operates under one segment, namely genetic diagnostic testing services. Its portfolio consists of various products and product candidates, such as ColoAlert, a colorectal cancer (CRC) screening stool-based DNA (deoxyribonucleic acid) test; PancAlert, a stool-based screening test for the detection of pancreatic cancer; GenoStrip, a platform technology to detect pathogens in environments on a molecular genetic basis. The Company competes with Exact Sciences, Epigenomics AG, Novigenix SA, GRAIL, Inc. and Agena Biosciences Inc.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- March 8th, 2021
- Public Since
- November 4th, 2021
- No. of Employees
- 19
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 2,319,353
- Address
- Sirius Gutenberg Park, MAINZ, 55129
- Web
- https://www.mainzbiomed.com/
- Phone
- +49 61315542860
- Auditors
- Reliant CPA PC
Upcoming Events for MYNZ
Similar to MYNZ
ADVANCED BIOMED
NASDAQ Capital Market
IMEI Technology Health
NASDAQ Capital Market
Akanda
NASDAQ Capital Market
Astrana Health
NASDAQ Capital Market
Basel Medical
NASDAQ Capital Market
FAQ
What is the Mainz Biomed NV share price?
As of Today at 21:51 UTC, shares in Mainz Biomed NV are trading at $3.22. This share price information is delayed by 15 minutes.
How has the Mainz Biomed NV share price performed this year?
Shares in Mainz Biomed NV last closed at $3.22 and the price had moved by -91.36% over the past 365 days. In terms of relative price strength the Mainz Biomed NV share price has underperformed the S&P500 Index by -91.87% over the past year.
What are the analyst and broker recommendations for Mainz Biomed NV?
The overall consensus recommendation for Mainz Biomed NV is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Mainz Biomed NV dividend yield?
Mainz Biomed NV does not currently pay a dividend.
Does Mainz Biomed NV pay a dividend?
Mainz Biomed NV does not currently pay a dividend.
When does Mainz Biomed NV next pay dividends?
Mainz Biomed NV does not currently pay a dividend.
How do I buy Mainz Biomed NV shares?
To buy shares in Mainz Biomed NV you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Mainz Biomed NV?
As of the previous close price of $3.22, shares in Mainz Biomed NV had a market capitalisation of $7.47m.
Where are Mainz Biomed NV shares listed?
Here are the trading details for Mainz Biomed NV:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: MYNZ
What kind of share is Mainz Biomed NV?
Based on an overall assessment of its quality, value and momentum Mainz Biomed NV is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Mainz Biomed NV share price forecast for 2025?
The analyst consensus target price for shares in Mainz Biomed NV is $14.00. That is 334.78% above the last closing price of $3.22.
Analysts covering Mainz Biomed NV currently have a consensus Earnings Per Share (EPS) forecast of -$6.55 for the next financial year.
Find out moreWhat is the trend in the Mainz Biomed NV share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Mainz Biomed NV. Over the past six months, its share price has underperformed the S&P500 Index by -70.57%.
As of the last closing price of $3.22, shares in Mainz Biomed NV were trading -64.08% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Mainz Biomed NV PE Ratio?
The Mainz Biomed NV PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $3.22.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Mainz Biomed NV?
We do not have data on Mainz Biomed NV's directors